• Formycon's nine-month 2026 pretax loss more than tripled to €186.6 million.
• Revenue more than doubled to €40 million, driven primarily by deferred FYB206 milestone payments and increasing royalty and commercialization revenue.
• The FDA accepted FYB206's application for review, with a market approval decision potentially expected in the third quarter of 2027.
• FY26 revenue guidance remains €60 million to €70 million, with results expected at the lower end of the range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2433320_en) on November 12, 2026, and is solely responsible for the information contained therein.